Michele Mishto

List of Publications by Year
in descending order

59 papers	2,620 citations	172457 29 h-index	189892 50 g-index
62 all docs	62 docs citations	62 times ranked	3221 citing authors

#	Article	IF	Citations
1	Database search engines and target database features impinge upon the identification of postâ€translationally <i>cisâ€</i>spliced peptides in HLA class I immunopeptidomes. Proteomics, 2022, 22, e2100226.	2.2	7
2	Predicting the Success of Fmoc-Based Peptide Synthesis. ACS Omega, 2022, 7, 23771-23781.	3.5	6
3	Proteasome-Generated cis-Spliced Peptides and Their Potential Role in CD8+ T Cell Tolerance. Frontiers in Immunology, 2021, 12, 614276.	4.8	13
4	Potential Mimicry of Viral and Pancreatic Î² Cell Antigens Through Non-Spliced and cis-Spliced Zwitter Epitope Candidates in Type 1 Diabetes. Frontiers in Immunology, 2021, 12, 656451.	4.8	11
5	Response: Commentary: An In Silicoâ€“In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. Frontiers in Immunology, 2021, 12, 679836.	4.8	9
6	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. Cell Reports, 2021, 36, 109312.	6.4	13
7	Commentary: Are There Indeed Spliced Peptides in the Immunopeptidome?. Molecular and Cellular Proteomics, 2021, 20, 100158.	3.8	11
8	Mechanistic diversity in MHC class I antigen recognition. Biochemical Journal, 2021, 478, 4187-4202.	3.7	10
9	ERâ€aminopeptidase 1 determines the processing and presentation of an immunotherapyâ€relevant melanoma epitope. European Journal of Immunology, 2020, 50, 270-283.	2.9	6
10	Large database for the analysis and prediction of spliced and non-spliced peptide generation by proteasomes. Scientific Data, 2020, 7, 146.	5.3	25
11	What We See, What We Do Not See, and What We Do Not Want to See in HLA Class I Immunopeptidomes. Proteomics, 2020, 20, 2000112.	2.2	12
12	Proteolytic dynamics of human 20S thymoproteasome. Journal of Biological Chemistry, 2019, 294, 7740-7754.	3.4	27
13	Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. Cells, 2019, 8, 262.	4.1	9
14	An in silicoâ€"in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. Frontiers in Immunology, 2019, 10, 2572.	4.8	38
15	Mapping the MHC Class Iâ€“Spliced Immunopeptidome of Cancer Cells. Cancer Immunology Research, 2019, 7, 62-76.	3.4	60
16	NMDA-receptor inhibition and oxidative stress during hippocampal maturation differentially alter parvalbumin expression and gamma-band activity. Scientific Reports, 2018, 8, 9545.	3.3	25
17	Why do proteases mess up with antigen presentation by re-shuffling antigen sequences?. Current Opinion in Immunology, 2018, 52, 81-86.	5.5	37
18	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Scientific Reports, 2017, 7, 43718.	3.3	35

#	Article	IF	Citations
19	Post-Translational Peptide Splicing and T Cell Responses. Trends in Immunology, 2017, 38, 904-915.	6.8	65
20	Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia, 2017, 58, 27-38.	5.1	131
21	Multi-level Strategy for Identifying Proteasome-Catalyzed Spliced Epitopes Targeted by CD8+ T Cells during Bacterial Infection. Cell Reports, 2017, 20, 1242-1253.	6.4	46
22	An Unexpected Major Role for Proteasome-Catalyzed Peptide Splicing in Generation of T Cell Epitopes: Is There Relevance for Vaccine Development?. Frontiers in Immunology, 2017, 8, 1441.	4.8	12
23	CD8⁺ TÂcells of <i>Listeria monocytogenesâ€‹</i>infected mice recognize both linear and spliced proteasome products. European Journal of Immunology, 2016, 46, 1109-1118.	2.9	39
24	Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing. Vaccine, 2016, 34, 5132-5140.	3.8	9
25	A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science, 2016, 354, 354-358.	12.6	322
26	Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. Scientific Reports, 2016, 6, 24032.	3.3	88
27	The T210M Substitution in the HLA-a*02:01 gp100 Epitope Strongly Affects Overall Proteasomal Cleavage Site Usage and Antigen Processing. Journal of Biological Chemistry, 2015, 290, 30417-30428.	3.4	20
28	The immunoproteasome Î²5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy. Brain, Behavior, and Immunity, 2015, 49, 188-196.	4.1	30
29	Quantitative time-resolved analysis reveals intricate, differential regulation of standard- and immuno-proteasomes. ELife, 2015, 4, e07545.	6.0	39
30	Towards a Liquid Self: How Time, Geography, and Life Experiences Reshape the Biological Identity. Frontiers in Immunology, 2014, 5, 153.	4.8	51
31	Lifelong maintenance of composition, function and cellular/subcellular distribution of proteasomes in human liver. Mechanisms of Ageing and Development, 2014, 141-142, 26-34.	4.6	21
32	Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis. Autoimmune Diseases, 2014, 2014, 1-12.	0.6	27
33	Modelling Proteasome and Proteasome Regulator Activities. Biomolecules, 2014, 4, 585-599.	4.0	10
34	Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. European Journal of Immunology, 2014, 44, 3508-3521.	2.9	107
35	Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities. Age, 2014, 36, 57-72.	3.0	20
36	Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?. Current Pharmaceutical Design, 2013, 19, 702-718.	1.9	27

#	Article	IF	Citations
37	Poly-Ub-Substrate-Degradative Activity of 26S Proteasome Is Not Impaired in the Aging Rat Brain. PLoS ONE, 2013, 8, e64042.	2.5	26
38	Immunoproteasome in cancer and neuropathologies: a new therapeutic target?. Current Pharmaceutical Design, 2013, 19, 702-18.	1.9	18
39	Driving Forces of Proteasome-catalyzed Peptide Splicing in Yeast and Humans. Molecular and Cellular Proteomics, 2012, 11, 1008-1023.	3.8	71
40	Immunoproteasome expression is induced in mesial temporal lobe epilepsy. Biochemical and Biophysical Research Communications, 2011, 408, 65-70.	2.1	29
41	Systems Biology and Longevity: An Emerging Approach to Identify Innovative Anti- Aging Targets and Strategies. Current Pharmaceutical Design, 2010, 16, 802-813.	1.9	76
42	Network, degeneracy and bow tie. Integrating paradigms and architectures to grasp the complexity of the immune system. Theoretical Biology and Medical Modelling, 2010, 7, 32.	2.1	71
43	Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. PLoS ONE, 2010, 5, e9287.	2.5	56
44	Evidence for Sub-Haplogroup H5 of Mitochondrial DNA as a Risk Factor for Late Onset Alzheimer's Disease. PLoS ONE, 2010, 5, e12037.	2.5	117
45	Studies on immunoproteasome in human liver. Part I: Absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis. Biochemical and Biophysical Research Communications, 2010, 397, 301-306.	2.1	31
46	The 20S Proteasome Splicing Activity Discovered by SpliceMet. PLoS Computational Biology, 2010, 6, e1000830.	3.2	63
47	Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with AlzheimerÊ¼s Disease. CNS Drugs, 2010, 24, 163-176.	5.9	44
48	Association of p53 polymorphisms and colorectal cancer: Modulation of risk and progression. European Journal of Surgical Oncology, 2009, 35, 415-419.	1.0	25
49	Modeling the in Vitro 20S Proteasome Activity: The Effect of PA28â€“Î±Î² and of the Sequence and Length of Polypeptides on the Degradation Kinetics. Journal of Molecular Biology, 2008, 377, 1607-1617.	4.2	28
50	Immunoproteasome in Macaca fascicularis: No Age-Dependent Modification of Abundance and Activity in the Brain and Insight into an in silico Structural Model. Rejuvenation Research, 2008, 11, 73-82.	1.8	7
51	Proteasome Modulation in Brain: A New Target for Anti-Aging Drugs?. Central Nervous System Agents in Medicinal Chemistry, 2007, 7, 236-240.	1.1	2
52	Genes, ageing and longevity in humans: Problems, advantages and perspectives. Free Radical Research, 2006, 40, 1303-1323.	3.3	66
53	Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiology of Aging, 2006, 27, 54-66.	3.1	184
54	A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biological Chemistry, 2006, 387, 417-429.	2.5	32

#	Article	IF	Citations
55	A Mathematical Model of Protein Degradation by the Proteasome. Biophysical Journal, 2005, 88, 2422-2432.	0.5	37
56	The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death and Differentiation, 2004, 11, 962-973.	11.2	84
57	Immunoproteasomes and immunosenescence. Ageing Research Reviews, 2003, 2, 419-432.	10.9	72
58	p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochemical and Biophysical Research Communications, 2002, 299, 539-541.	2.1	38
59	Age dependent impact of LMP polymorphisms on TNFÎ±-induced apoptosis in human peripheral blood mononuclear cells. Experimental Gerontology, 2002, 37, 301-308.	2.8	22